EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study

Hirofumi Miyake iD, Akira Onishi iD, Hideaki Tsuji iD, Takuya Kotani iD, Yumiko Wada, Yuji Nozaki iD, Toshihiko Shiga, Shigeru Iwata iD, Takao Fujii, Yasuhiro Kato iD, Eri Itotagawa, Shuji Sumitomo iD und 4 weitere

Modern Rheumatology · 04.11.2026 · 36 (6) · 972-978

DOI: 10.1093/mr/roag053 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Rheumatology, online erschienen am 26.06.2026. Verfasst von Hirofumi Miyake und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Tenri Hospital, Tenri, Japan. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Glucocorticoids, Immunosuppressive Agents, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To identify the factors associated with flares after glucocorticoid (GC) reduction in systemic lupus erythematosus (SLE) and to determine whether belimumab (BLM) influences this risk.

Methods

Using the ANSWER-SLE cohort, this retrospective, multicentre study enrolled 388 patients with a GC reduction from ≤5 mg/day. The primary outcome was the time to an overall flare (SLE Disease Activity Index 2000 [SLEDAI-2K] increase of ≥3 or a GC escalation). Multivariable Cox models identified factors associated with an overall flare. Propensity score-based matching weights were applied, and weighted Cox models assessed the association between BLM and flare risk.

Results

During a 1-year follow-up, 133 overall flares occurred (1-year cumulative incidence 39.9%). A higher clinical SLEDAI (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.03–1.17), Systemic Lupus International Collaborating Clinics Damage Index (SDI) (HR 1.11, 95% CI 1.01–1.22), and GC dose reduction (HR 1.40, 95% CI 1.15–1.70) were associated with an increased overall flare risk. GC reductions of >1 mg were associated with flare (HR 2.53, 95% CI 1.54–4.15). In the weighted analyses, BLM was not associated with an overall flare (HR 0.83, 95% CI 0.51–1.34).

Conclusions

In patients with SLE, carefully tapering GC doses from ≤5 mg/day according to disease activity and organ damage may be important, whereas BLM was not associated with a reduced flare risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicGlucocorticoidsImmunosuppressive AgentsAntibodies, Monoclonal, HumanizedDrug TaperingHumansFemaleRetrospective StudiesAdultRisk FactorsMaleMiddle AgedSymptom Flare UpSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

belimumabclinical activitydamageflareglucocorticoidsystemic lupus erythematosustapering

Substanzen

GlucocorticoidsbelimumabImmunosuppressive AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of General Internal Medicine, Tenri Hospital, Tenri, Japan.
  • Department of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Department of Hematology and Rheumatology, Kindai University Hospital, Sakai, Japan.
  • Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.

ORCID-Profile: Hirofumi Miyake, Akira Onishi, Hideaki Tsuji, Takuya Kotani, Yuji Nozaki, Shigeru Iwata, Yasuhiro Kato, Shuji Sumitomo, Hideki Oka, Wataru Yamamoto

Zitieren

APA

Miyake, H., Onishi, A., Tsuji, H., Kotani, T., Wada, Y., Nozaki, Y., Shiga, T., Iwata, S., Fujii, T., Kato, Y., Itotagawa, E., Sumitomo, S., Oka, H., Yamamoto, W., Katsushima, M., & Hashimoto, M. (2026). Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study. Modern Rheumatology, 36(6), 972-978. https://doi.org/10.1093/mr/roag053

Vancouver

Miyake H, Onishi A, Tsuji H, Kotani T, Wada Y, Nozaki Y, et al. Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study. Modern Rheumatology. 2026;36(6):972-978. doi:10.1093/mr/roag053

BibTeX
@article{Miyake2026,
  author = {Miyake, Hirofumi and Onishi, Akira and Tsuji, Hideaki and Kotani, Takuya and Wada, Yumiko and Nozaki, Yuji and Shiga, Toshihiko and Iwata, Shigeru and Fujii, Takao and Kato, Yasuhiro and Itotagawa, Eri and Sumitomo, Shuji and Oka, Hideki and Yamamoto, Wataru and Katsushima, Masao and Hashimoto, Motomu},
  title = {Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study},
  journal = {Modern Rheumatology},
  year = {2026},
  volume = {36},
  number = {6},
  pages = {972--978},
  doi = {10.1093/mr/roag053}
}
Kostenlos starten →